source
- Replimune to file third FDA application for RP1 cancer therapy after productive talksReplimune announced it will submit a third marketing application for its experimental cancer therapy RP1, following what the company described as productive discussions with the Food and Drug Admin…
- Allogene CEO David Chang to step down as Agios drug misses mid-stage trial resultsAllogene announced that its chief executive, co‑founder David Chang, will leave the role after an eight‑year tenure. Chang, who previously worked at Kite Pharma, will remain on the company’s board…